Tesamorelin half-life & pharmacokinetics

Reported half-life

Approximately 26-38 minutes plasma half-life — longer than sermorelin (5-12 min) due to N-terminal trans-3-hexenoyl protection against DPP-4 cleavage, shorter than CJC-1295 no-DAC (30 min) and materially shorter than DAC-modified CJC-1295 (6-8 days). Once-daily subcutaneous dosing produces sustained but pulsatile-preserving GH-axis activation.

The half-life and pharmacokinetic profile of Tesamorelin reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (FDA-approved route)
• Intramuscular injection (not standard)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic stabilised analogue of full-length human GHRH (1-44) with N-terminal trans-3-hexenoyl modification for protease resistance; FDA-approved for HIV-associated lipodystrophy under the trade name Egrifta.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Tesamorelin acts as follows:

Tesamorelin is structurally distinct from sermorelin and CJC-1295 in retaining the full 44-amino-acid sequence of native human GHRH rather than the 1-29 truncation. The protease-resistance modification is a single chemical addition — a trans-3-hexenoyl group covalently attached to the N-terminal tyrosine through an amide bond, replacing the unmodified N-terminal amine. This single modification blocks dipeptidyl peptidase-4 (DPP-4) cleavage at the otherwise-vulnerable His-Ala bond, extending the plasma half-life from approximately 5 minutes (native GHRH) to 26-38 minutes (tesamorelin).

See the full Tesamorelin research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.